<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110651</url>
  </required_header>
  <id_info>
    <org_study_id>D-Pre-HCQ-D104</org_study_id>
    <nct_id>NCT05110651</nct_id>
  </id_info>
  <brief_title>The Danish Pre-HCQ COVID Dialysis Study</brief_title>
  <official_title>The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for Prevention of COVID19 in Dialysis-treated Patients With End-stage Renal Disease - A Multicenter Parallel-group Open Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Carlson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hydroxychloroquine has been shown to inhibit replication of SARS-CoV-2 in vitro. The&#xD;
      presented multicenter parallel-group open-label randomized clinical trial aims to investigate&#xD;
      the efficacy of prophylactic hydroxychloroquine on mitigation of risk of hospitalization due&#xD;
      to COVID-19 in patients with end-stage renal disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The emergence of a novel betacoronavirus designated severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2) has led to a global pandemic with profound implications for public&#xD;
      health. Despite sweeping containment measures, spread of infection is ongoing, with potential&#xD;
      ramifications pertaining to availability of health care resources. Preliminary data from&#xD;
      Wuhan, China and Northern Italy indicate particular vulnerability of patients &gt;60 years with&#xD;
      pre-existing comorbidity leading to increased risk of hospitalization and death. Currently,&#xD;
      no specific treatment has demonstrated efficacy against infection with SARS-CoV-2 in a&#xD;
      clinical trial. However, chloroquine has been shown to inhibit both viral entry and&#xD;
      replication in infection with SARS-CoV-2 in vitro; albeit the specific mechanisms remain&#xD;
      unchartered. Chloroquine is an amine acidotropic form of quinine. Previously a first-choice&#xD;
      front-line drug for the treatment and prophylaxis of malaria, chloroquine remains one of the&#xD;
      most prescribed drugs worldwide. The possible benefit of prophylactic treatment with&#xD;
      hydroxychloroquine for mitigation of risk of manifest SARS-COV-2 remains untested. The&#xD;
      on-going pandemic entails particular risk for patients on chronic dialysis; chronic dialysis&#xD;
      is both associated with profound comorbidity but also requirement of continued ambulant&#xD;
      hospital based treatment leading to increased exposure. Consequently, the potential benefit&#xD;
      of preventative measures is greatly increased.&#xD;
&#xD;
      Aims and objectives The main objective of the following multicenter parallel-group open-label&#xD;
      randomized clinical trial aims to investigate the possible benefit of initiating prophylactic&#xD;
      hydroxychloroquine versus no treatment in patients on chronic dialysis for mitigation of risk&#xD;
      related to SARS-CoV-2. The anticipated results will provide evidence as to the&#xD;
      appropriateness of initiating prophylactic treatment for prevention of symptomatic SARS-CoV-2&#xD;
      in a vulnerable comorbid population with direct and immediate implications for clinical&#xD;
      management and public health care beyond renal failure.&#xD;
&#xD;
      Methods A total of 568 dialysis-treated patients with end-stage renal disease will be&#xD;
      recruited from all dialysis centers (including satellites) in the Capital region. Patients&#xD;
      will be randomized to either oral hydroxychloroquinesulphate 200mg once daily or no treatment&#xD;
      for three months. The study is planned as a multicenter, open-label, parallel-group pragmatic&#xD;
      randomized clinical study.&#xD;
&#xD;
      Additionally, 100 participants on chronic in-center hemodialysis treatment will be invited to&#xD;
      participate in a sub-study focused on SARS-CoV-2 screening and prevention. Patients will&#xD;
      undergo screening based on oro-pharyngeal sampling twice weekly. If ≥ 20% of infected&#xD;
      patients are identified prior to development of symptoms, results will be applied to advise&#xD;
      early SARS-CoV-2 screening in all chronic in-center hemodialysis patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 10, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter parallel-group open-label randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization due to SARS-CoV-2 infection</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients hospitalized due to COVID-19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 infection</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with verified SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>3 months</time_frame>
    <description>SARS-CoV-2 viral count as defined by real-time RNA polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Number of deaths within the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of mechanical ventilation</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients requiring mechanical ventilation due to SARS-CoV-2 infection within the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to intensive care</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients admitted to intensive care due to SARS-CoV-2 infection within the study period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Duration in days of hospitalization due to SARS-CoV-2 infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>3 months</time_frame>
    <description>Duration in day of mechanical ventilation due to SARS-CoV-2 infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of admission to intensive care</measure>
    <time_frame>3 months</time_frame>
    <description>Duration in days of admission to intensive care due to SARS-CoV-2 infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone marrow suppression</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with leucopeni &lt; 3000/μL within the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic dysfunction</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with hepatic dysfunction as defined by an alanine transaminaease &gt; 250U/I within the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac injury</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with evidence of cardiac injury (creatinine kinase-myocardial band &gt; 5μg/L) within the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Sudden cardiac death</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with sudden cardiac death within the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>QTc prolongation</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with QTc prolongation (Bazett's formula; &gt;&gt; 450 ms in males and 460 ms in females)</description>
  </other_outcome>
  <other_outcome>
    <measure>Positiv SARS-CoV-2 antibody</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with positive SARS-CoV-2 antibody at 3 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID-19</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral hydroxychloroquine 200mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels &gt; 2000ng/ml</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years on chronic dialysis due to end-stage renal disease.&#xD;
&#xD;
          -  Competence to understand the study rationale, including potential risks and benefits&#xD;
             associated with treatment, necessary for written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior verified SARS-CoV-2 infection.&#xD;
&#xD;
          -  Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines&#xD;
&#xD;
          -  Electrocardiogram with QTc (Bazett's formula) &gt; 450 ms in males and 460 ms in females&#xD;
&#xD;
          -  Patients reliant on digoxin or amiodarone treatment&#xD;
&#xD;
          -  Pre-existing psoriasis&#xD;
&#xD;
          -  Any pre-existing maculopathy with vision reduction&#xD;
&#xD;
          -  Prior sensorineural hearing loss&#xD;
&#xD;
          -  Pre-existing severe liver insufficiency (spontaneous international normalized ratio&#xD;
             &gt;1.5 within the last year)&#xD;
&#xD;
          -  Pre-existing epileptic disease requiring anti-epileptic medication&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Insurmountable Language Barrier&#xD;
&#xD;
          -  Participation in other ongoing intervention trials investigating COVID19-related&#xD;
             outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Carlson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Zealand Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Nicholas Carlson</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Aggregated de-identified individual participant data for primary and secondary outcomes measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Aggregated data will be available within 12 months of study completion</ipd_time_frame>
    <ipd_access_criteria>All data access requests via email. Requestors will be required to sign a Data Access Agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

